<DOC>
	<DOCNO>NCT03099083</DOCNO>
	<brief_summary>The objective non-interventional , observational study assess effect adalimumab health-related quality life participant Psoriasis Korea .</brief_summary>
	<brief_title>Real-World Outcome Psoriasis Subjects Korea Adalimumab</brief_title>
	<detailed_description />
	<mesh_term>Psoriasis</mesh_term>
	<mesh_term>Adalimumab</mesh_term>
	<criteria>Participant diagnosis Psoriasis investigator . Participant ( local definition accord adalimumab label ) compliance eligibility adalimumab base local label . Participant must able willing provide write informed consent comply requirement study protocol . Participants pregnant breast feeding enrolment wish become pregnant next 24 week . Participation Psoriasisrelated clinical trial time enrolment , baseline point study period . Participants , investigator 's view , may able accurately report questionnaire</criteria>
	<gender>All</gender>
	<minimum_age>19 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>March 2017</verification_date>
	<keyword>Adalimumab</keyword>
	<keyword>Psoriasis</keyword>
	<keyword>Humira</keyword>
	<keyword>Korea</keyword>
</DOC>